XTX Topco Ltd Invests $412,000 in Fate Therapeutics, Inc. (NASDAQ:FATE)

XTX Topco Ltd bought a new stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 249,800 shares of the biopharmaceutical company's stock, valued at approximately $412,000. XTX Topco Ltd owned 0.22% of Fate Therapeutics at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new position in Fate Therapeutics in the fourth quarter valued at $40,000. FPC Investment Advisory Inc. bought a new position in shares of Fate Therapeutics in the fourth quarter valued at about $44,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Fate Therapeutics in the fourth quarter valued at approximately $58,000. Intech Investment Management LLC lifted its holdings in shares of Fate Therapeutics by 27.5% during the fourth quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company's stock worth $65,000 after buying an additional 8,497 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Fate Therapeutics by 30.6% during the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 10,511 shares in the last quarter. 97.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Wedbush reiterated a "neutral" rating and set a $5.00 price objective on shares of Fate Therapeutics in a research note on Thursday, March 6th. StockNews.com lowered shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. Stifel Nicolaus cut their price target on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a report on Thursday, March 6th. Finally, Wells Fargo & Company lowered their target price on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, Fate Therapeutics presently has an average rating of "Hold" and an average target price of $5.43.

Fate Therapeutics Price Performance

Shares of NASDAQ FATE traded up $0.02 during mid-day trading on Thursday, reaching $1.35. 1,549,992 shares of the company's stock were exchanged, compared to its average volume of 2,324,966. The firm has a market capitalization of $154.72 million, a price-to-earnings ratio of -0.82 and a beta of 2.41. The firm has a 50-day moving average price of $1.04 and a two-hundred day moving average price of $1.72. Fate Therapeutics, Inc. has a 52 week low of $0.66 and a 52 week high of $5.92.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.13. The firm had revenue of $1.86 million for the quarter, compared to analysts' expectations of $1.57 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. As a group, sell-side analysts forecast that Fate Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.